Last reviewed · How we verify
Azedra
At a glance
| Generic name | Azedra |
|---|---|
| Also known as | iobenguane I-131 |
| Sponsor | David Bushnell |
| Target | Sodium-dependent noradrenaline transporter |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | discontinued |
Approved indications
- Paraganglioma
- Pheochromocytoma
Common side effects
Key clinical trials
- A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma (Phase 2)
- A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma (Phase 1)
- 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol (N/A)
- A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma (Phase 2)
- A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors (Phase 1)
- Expanded Access Program of AZEDRA (Ultratrace Iobenguane I131) in Subjects With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma: A Sub-study of Protocol MIP-IB12B (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |